Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Jen‐Shi Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9756-3974; OpenAlex author ID A5053209984, A5122721618. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper, 1 trial · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: 2 papers · 2022: 6 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 29

  1. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  2. Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jfma.2026.01.057↗
  3. The efficacy and safety profile of third-line treatment in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.01.012↗
  4. Outcomes of Liposomal Irinotecan With 5-FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status. Co-author DOI 10.21873/cdp.10430↗
  5. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Last author DOI 10.1016/j.bj.2023.100696↗
  6. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  7. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which P… Co-author DOI 10.1016/j.ijrobp.2023.02.061↗
  8. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  9. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  10. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Co-author DOI 10.1016/j.ejca.2022.06.043↗
  11. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  12. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  13. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  14. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  15. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: Fr… Co-author DOI 10.1016/j.radonc.2021.02.037↗
  16. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  17. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Co-author DOI 10.1016/j.ejca.2019.10.023↗
  18. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
  19. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan. Co-author DOI 10.1002/cam4.2094↗
  20. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic … Co-author DOI 10.1002/cam4.2254↗
  21. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1002/cam4.2483↗
  22. Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2… Co-author DOI 10.2147/cmar.s196300↗
  23. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Co-author DOI 10.3390/cancers11010057↗
  24. Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. First author DOI 10.3390/cancers10110432↗
  25. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with E… Co-author DOI 10.3390/cancers10120501↗
  26. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  27. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer. Last author PMID 25368287↗
  28. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  29. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced… Co-author DOI 10.1016/j.ijrobp.2010.10.034↗

Trials 1

  1. A Phase II Study of Locally Advanced Pancreatic Cancer Principal investigator NCT01867892↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen‐Chi Chou · 21 shared papers, 2014–2026 · strength 2.95
  2. Yen‐Yang Chen · 19 shared papers, 2018–2026 · strength 2.59
  3. Tai‐Jan Chiu · 13 shared papers, 2021–2026 · strength 2.37
  4. Yan‐Shen Shan · 15 shared papers, 2011–2026 · strength 1.98
  5. Chung‐Pin Li · 13 shared papers, 2020–2026 · strength 1.91
  6. Li‐Tzong Chen · 14 shared papers, 2011–2026 · strength 1.84
  7. Nai‐Jung Chiang · 12 shared papers, 2020–2026 · strength 1.74
  8. Li‐Yuan Bai · 11 shared papers, 2021–2026 · strength 1.64
  9. Yung‐Yeh Su · 9 shared papers, 2021–2026 · strength 1.37
  10. Shih‐Hung Yang · 9 shared papers, 2021–2024 · strength 1.25
  11. Yu‐Shin Hung · 8 shared papers, 2018–2026 · strength 1.09
  12. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  13. Pei‐Hung Chang · 7 shared papers, 2018–2019 · strength 0.66
  14. Chieh-Ying Chang · 2 shared papers, 2025–2026 · strength 0.62
  15. Chi-Chen Lan · 2 shared papers, 2025–2026 · strength 0.54
  16. Kun‐Ming Rau · 2 shared papers, 2020–2026 · strength 0.35
  17. Yao‐Yu Hsieh · 1 shared paper, 2026 · strength 0.25
  18. I‐Wei Ho · 1 shared paper, 2026 · strength 0.25
  19. Yen‐Feng Chiu · 2 shared papers, 2011–2023 · strength 0.20
  20. Hui-Ju Ch’ang · 2 shared papers, 2011–2023 · strength 0.20
  21. Tsann‐Long Hwang · 2 shared papers, 2011–2023 · strength 0.20
  22. Ching‐Fu Chang · 2 shared papers, 2019 · strength 0.19
  23. Pei‐Wei Huang · 2 shared papers, 2019 · strength 0.19
  24. Hsin‐Chen Lin · 1 shared paper, 2024 · strength 0.19
  25. Chien‐Jui Huang · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.